Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

Applying for disability benefits is complicated. Blogger Trevis Gleason encourages people with multiple sclerosis to reach ...

Daily propionic acid supplements lowered levels of a nerve damage marker in people with MS, but clinical benefits remain ...

A review of a disability benefit is not expected to make "crude proposals" on changes to claimants' payments, the minister ...

Nanocurcumin was linked to better disability scores in small RRMS trials, but researchers say larger studies are needed.

Eating a nutritious diet boosts overall health and helps with multiple sclerosis management. But knowing what not to eat may ...

Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system ...

Add Yahoo as a preferred source to see more of our stories on Google. The smartphone app showed it was able to track certain digital biomarkers in MS patients. Credit: daily_creativity / ...

MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE ...

Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...